How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.

Autor: Haggstrom L; Medical Oncology, Prince of Wales Hospital Nelune Comprehensive Cancer Centre, Sydney, New South Wales, Australia.; School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia., Lee YC; Medical Oncology, Prince of Wales Hospital Nelune Comprehensive Cancer Centre, Sydney, New South Wales, Australia.; School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia., Scott C; The University of Melbourne, Melbourne, Victoria, Australia.; Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Harter P; Department of Gynecology and Gynecologic Oncology, Ev, Kliniken Essen-Mitte, Essen, Germany.; Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom, Essen, Germany., Woelber L; Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom, Essen, Germany.; Department of Gynecology, University Medical Center Hamburg - Eppendorf, Hamburg, Germany., Ledermann J; UCL Cancer Institute, London, UK.; University College London Hospitals NHS Foundation Trust, London, UK., Gourley C; Institute of Genetics and Cancer, Cancer Research UK Edinburgh Centre, Edinburgh, UK., McNeish IA; Imperial College London Department of Surgery and Cancer, London, UK., Amant F; Division of Gynecologic Oncology, UZ Leuven, Leuven, Belgium.; Department of Gynecologic Oncology, Center for Gynecologic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Ray-Coquard I; Centre Léon Bérard, Lyon, France.; Universite Claude Bernard Lyon, Villeurbanne, France., Leary A; Institut National de la Santé et de la Recherche Médicale, Institut Gustave-Roussy, Villejuif, France., Oza AM; Medical Oncology & Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada., Tinker A; BC Cancer - Vancouver, Vancouver, British Columbia, Canada., González Martin A; Grupo Español de Investigación en Cancer Ginecológico (GEICO), Madrid, Spain.; Medical Oncology Department, Clínica Universidad de Navarra Cancer Center, Madrid, Spain., Cecere SC; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.; Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Naples, Italy., Pignata S; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.; Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Naples, Italy., Colombo N; Gynecologic Oncology Program, European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico IRCCS, Milan, Italy.; School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy., Yoshida H; Department of Gynecologic Oncology, Saitama Medical University, Iruma-gun, Japan.; GOTIC - North Kanto Gynecologic Cancer Clinical Trials Consortium, Saitama, Japan., Marth C; Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria., Rosengarten O; Medical Gyneco-Oncology Unit, Shaare Zedek Medical Center, Jerusalem, Israel., Moore KN; Sarah Cannon Research Institute, Nashville, Tennessee, USA., Gómez-García EM; Centro de Tratamiento de Cancer Metepec, Toluca, Mexico., Tan D; Yong Loo Lin School of Medicine, National University of Singapore Centre for Cancer Research, Singapore., Friedlander ML; Medical Oncology, Prince of Wales Hospital Nelune Comprehensive Cancer Centre, Sydney, New South Wales, Australia m.friedlander@unsw.edu.au.; School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.

Publikováno v: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2024 Dec 02; Vol. 34 (12), pp. 1932-1939. Date of Electronic Publication: 2024 Dec 02.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population.

Autor: Merry E; Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK Eve.Merry@nhs.net., Kesmez RT; Bart's Cancer Institute, Queen Mary University of London, London, UK., Yu T; Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK., Flynn M; Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK., Ledermann J; Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK.; UCL Cancer Institute, London, UK., Lockley M; Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK.; Bart's Cancer Institute, Queen Mary University of London, London, UK., Macdonald N; Gynaecological Oncology, University College London Hospitals NHS Foundation Trust, London, UK., McCormack M; Oncology, University College London Hospitals NHS Foundation Trust, London, UK., Nicum S; Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK., Crusz S; Medical Oncology, Barts Health NHS Trust, London, UK., Miller R; Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK.; Medical Oncology, Barts Health NHS Trust, London, UK.

Publikováno v: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2024 Sep 03. Date of Electronic Publication: 2024 Sep 03.

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Autor: Buck, M, Dean, A, Friedlander, M L, Goh, J C, Harnett, P, Kichenadasse, G, Scott, C L, Denys, H, Dirix, L, Vergote, I, Elit, L, Ghatage, P, Oza, A M, Plante, M, Provencher, D, Weberpals, J I, Welch, S, Floquet, A, Gladieff, L, Joly, F, Leary, A, Lortholary, A, Lotz, J, Medioni, J, Tredan, O, You, B, El-Balat, A, Hänle, C, Krabisch, P, Neunhöffer, T, Pölcher, M, Wimberger, P, Amit, A, Kovel, S, Leviov, M, Safra, T, Shapira-Frommer, R, Stemmer, S, Bologna, A, Colombo, N, Lorusso, D, Pignata, S, Sabbatini, R F, Scambia, G, Tamberi, S, Zamagni, C, Fong, P C, O'Donnell, A, Gancedo, M Amenedo, Herraez, A Casado, Garcia-Donas, J, Guerra, E M, Oaknin, A, Palacio, I, Romero, I, Sanchez, A, Banerjee, S N, Clamp, A, Drew, Y, Gabra, H G, Jackson, D, Ledermann, J A, McNeish, I A, Parkinson, C, Powell, M, Aghajanian, C, Armstrong, D K, Birrer, M J, Buss, M K, Chambers, S K, Chen, L-m, Coleman, R L, Holloway, R W, Konecny, G E, Ma, L, Morgan, M A, Morris, R T, Mutch, D G, O'Malley, D M, Slomovitz, B M, Swisher, E M, Vanderkwaak, T, Vulfovich, M, Coleman, Robert L, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, O'Malley, David M, Armstrong, Deborah K, Garcia-Donas, Jesus, Swisher, Elizabeth M, Floquet, Anne, Konecny, Gottfried E, McNeish, Iain A, Scott, Clare L, Cameron, Terri, Maloney, Lara, Isaacson, Jeff, Goble, Sandra, Grace, Caroline, Harding, Thomas C, Raponi, Mitch, Sun, James, Lin, Kevin K, Giordano, Heidi, Ledermann, Jonathan A

Publikováno v: In The Lancet 28 October-3 November 2017 390(10106):1949-1961

Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK

Autor: Khoja, L. ^∗, Nolan, K. ^†, Mekki, R. ^†, Milani, A. ^‡, Mescallado, N. ^∗, Ashcroft, L. ^§, Hasan, J. ^∗, Edmondson, R. ^¶, Winter-Roach, B. ^∗, Kitchener, H.C. ^¶, Mould, T. ^‡, Hutson, R. ^†, Hall, G. ^†, Clamp, A.R. ^∗, Perren, T. ^†, Ledermann, J. ^‡, Jayson, G.C. ^∗

Publikováno v: In Clinical Oncology December 2016 28(12):760-765